Epstein RS - Search Results

1

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. Among authors: epstein rs. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.

2

Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Komatsu Y, Ahn DH, Epstein RS, Halim AB, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. Among authors: epstein rs. Future Oncol. 2024;20(36):2811-2822. doi: 10.1080/14796694.2024.2364504. Epub 2024 Jun 17. Future Oncol. 2024. PMID: 38884254 Free PMC article. Clinical Trial.

3

Analysis of Ly5 chromosome 1 position using allelic differences and recombinant inbred mice.

Zebedee SL, Barritt D, Epstein R, Raschke WC. Zebedee SL, et al. Eur J Immunogenet. 1991 Jun;18(3):155-63. doi: 10.1111/j.1744-313x.1991.tb00015.x. Eur J Immunogenet. 1991. PMID: 1834169

4

Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms.

Zeidan AM, Perepezko K, Salimi T, Washington T, Epstein RS. Zeidan AM, et al. Among authors: epstein rs. Ther Adv Hematol. 2024 Jul 30;15:20406207241257313. doi: 10.1177/20406207241257313. eCollection 2024. Ther Adv Hematol. 2024. PMID: 39091323 Free PMC article.

5

Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes.

Zeidan AM, Joshi N, Kale H, Wang WJ, Corman S, Salimi T, Epstein RS. Zeidan AM, et al. Among authors: epstein rs. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):670-679. doi: 10.1016/j.clml.2022.04.016. Epub 2022 Apr 22. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35614009 Free article.

6

Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.

Epstein RS, Nelms J, Moran D, Girman C, Huang H, Chioda M. Epstein RS, et al. Cancer Treat Res Commun. 2022;31:100555. doi: 10.1016/j.ctarc.2022.100555. Epub 2022 Apr 4. Cancer Treat Res Commun. 2022. PMID: 35421820 Free article.

7

Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.

Harvey MJ, Zhong Y, Morris E, Beverage JN, Epstein RS, Chawla AJ. Harvey MJ, et al. Among authors: epstein rs. PLoS One. 2022 Jan 24;17(1):e0261336. doi: 10.1371/journal.pone.0261336. eCollection 2022. PLoS One. 2022. PMID: 35073335 Free PMC article.

8

Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.

Epstein RS, Weerasinghe RK, Parrish AS, Krenitsky J, Sanborn RE, Salimi T. Epstein RS, et al. J Med Econ. 2022 Jan-Dec;25(1):108-118. doi: 10.1080/13696998.2021.2020570. J Med Econ. 2022. PMID: 34927520 Free article.

9

Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?

Zeidan AM, Salimi T, Epstein RS. Zeidan AM, et al. Among authors: epstein rs. Future Oncol. 2021 Dec;17(36):5163-5175. doi: 10.2217/fon-2021-0936. Epub 2021 Oct 12. Future Oncol. 2021. PMID: 34636250 Review.

10

Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs.

Epstein RS. Epstein RS. Clinicoecon Outcomes Res. 2021 Sep 10;13:801-807. doi: 10.2147/CEOR.S317687. eCollection 2021. Clinicoecon Outcomes Res. 2021. PMID: 34531668 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

128 results

Search Page

Filters